41658-03-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Propynoic acid, 3-bromo-, ethyl ester is used as a key intermediate in the synthesis of pharmaceuticals for its ability to readily participate in organic reactions, contributing to the development of new medications and therapeutic agents.
Used in Agricultural Chemicals Industry:
In the agricultural chemicals sector, 2-Propynoic acid, 3-bromo-, ethyl ester serves as a crucial component in the production of various agrochemicals, aiding in the creation of effective pest control and crop protection products.
Used in Fragrance and Flavoring Industry:
2-Propynoic acid, 3-bromo-, ethyl ester is also utilized in the manufacture of fragrances and flavoring compounds, capitalizing on its reactivity to produce a wide array of scent and taste profiles for various consumer products.
However, it is important to handle 2-Propynoic acid, 3-bromo-, ethyl ester with care due to its potential hazards and toxic properties, ensuring safety in its application across different industries.

Upstream product

• 623-47-2 propynoic acid ethyl ester 

Downstream Products

• 1235344-15-6 ethyl 4-bromo-5-iodo-1-(4-methoxyphenyl)-1H-pyrazole-3-carboxylate 
• 1235344-12-3 ethyl 3-bromo-5-iodo-1-(4-methoxyphenyl)-1H-pyrazole-4-carboxylate 
• 1609648-71-6 ethyl 3-(2-(tert-butyldimethylsilyl)-1-(N,N-dimethylsulfamoyl)-5-((4-methoxy-3,5-dimethylphenyl)sulfinyl)imidazol-4-yl)prop-2-ynoate 
• 2216-94-6 phenylpropynoic acid ethyl ester 
• 1620636-42-1 (E)-ethyl 5-p-tolylpent-4-en-2-ynoate 
• 26218-40-6 3,4-bis(4-methoxyphenyl)-1,2,5-oxadiazole-2-oxide 

Relevant academic research and scientific papers

Surfactant Micelles Enable Metal-Free Spirocyclization of Keto-Ynamides and Access to Aza-Spiro Scaffolds in Aqueous Media

Micellar solutions of cetyltrimethylammonium bromide (CTAB) surfactant allow the spirocyclization of keto-ynamides in an aqueous medium without recourse to transition-metal catalysis, enabling access in water to naturally occurring aza-spiro compounds with potential in drug discovery. The reaction was monitored by dynamic light scattering (DLS) and cryogenic transmission electron microscopy (cryo-TEM), which determined the morphology and change in size of the micelles before and after incorporation of the substrate and achievement of 5-endo-dig cyclization inside the micelles.

Synthesis, characterization and computational evaluation of bicyclooctadienes towards molecular solar thermal energy storage

Molecular solar-thermal energy storage (MOST) systems are based on photoswitches that reversibly convert solar energy into chemical energy. In this context, bicyclooctadienes (BODs) undergo a photoinduced transformation to the corresponding higher energy

Discovery and Characterization of 1 H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy

The prostanoid EP4 receptor is one of the key receptors associated with inflammatory mediator PGE2-elicited immunosuppression in the tumor microenvironment. Blockade of EP4 signaling to enhance immunity-mediated tumor elimination has recently emerged as a promising strategy for cancer immunotherapy. In our efforts to discover novel subtype-selective EP4 antagonists, we designed and synthesized a class of 1H-1,2,3-triazole-based ligands that display low nanomolar antagonism activity toward the human EP4 receptor and excellent subtype selectivity. The most promising compound 59 exhibits single-digit nanomolar potency in the EP4 calcium flux and cAMP-response element reporter assays and effectively suppresses the expression of multiple immunosuppression-related genes in macrophage cells. On the basis of its favorable ADMET properties, compound 59 was chosen for further in vivo biological evaluation. Oral administration of compound 59 significantly inhibited tumor growth in the mouse CT26 colon carcinoma model accompanied by enhanced infiltration of cytotoxic T lymphocytes in the tumor tissue.

Polysubstituted triazole formate derivative and application thereof

The invention discloses a compound shown as formula I in the specification, or a stereoisomer, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a metabolite, or a deuterated derivative thereof. Belonging to the field of pharmaceutical

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Metal-free synthesis of activated ynesulfonamides and tertiary enesulfonamides

An operationally simple synthesis of activated ynesulfonamides and enesulfonamides is described. Ynesulfonamides can be obtained through reaction of sulfonylamides with activated bromoalkynes and Triton B in a short time at room temperature. Likewise, terminal alkynes react with sulfonylamides to provide enesulfonamides. Z/E enesulfonamides can be transformed exclusively into E enesulfonamides.

Synthesis of Benzofurans and Benzoxazoles through a [3,3]-Sigmatropic Rearrangement: O-NHAc as a Multitasking Functional Group

The synthesis of heterocycles relies heavily on diverse sigmatropic rearrangements triggered by the cleavage of X-Y (X, Y = C, O, N, S, I) bonds. However, a unified rearrangement approach for constructing heterocyclic libraries is highly desirable. Encouraged by computational analysis of [3,3]-sigmatropic rearrangements, we can now rapidly synthesize oxa-heterocycles by treating N-phenoxyacetamides (Ph-ONHAc) with compounds containing an sp-hybridized carbon. The generality of the process is illustrated by the late-stage diversification of natural products, including estrone and an approved drug. A combination of experimental and computational studies revealed that the reactions proceed through a facile Claisen-like [3,3]-sigmatropic rearrangement/annulation process.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Diastereoselective Copper-Mediated Cross-Couplings between Stereodefined Secondary Alkylcoppers with Bromoalkynes

A copper(I)-mediated cross-coupling of stereodefined secondary alkyllithiums with bromoalkynes provided stereodefined alkynes with high diastereoselectivity (dr up to 98:2). This cross-coupling was extended to various secondary alkyllithiums bearing a remote oxygen functionality, and the alkyne synthesis was also performed with optically enriched alkyl iodides (up to 99% ee) providing, after cross-coupling, alkynes bearing two stereocenters (dr = 93:7; up to 99% ee).